Actively Recruiting
Phase III Trial Comparing GS101 Injection and Dupixent for Moderate-to-Severe Atopic Dermatitis
Led by Jiangsu Genscend Biopharmaceutical Co., Ltd · Updated on 2026-10-15
572
Participants Needed
1
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multicenter, randomized, double-blinded Phase III study comparing GS101 injection with Dupixent in adults with moderate-to-severe atopic dermatitis. The study aims to evaluate the treatments effects on the skin condition, enrolling approximately 572 participants who meet specific disease severity criteria. Participants will receive either GS101 injection or Dupixent, both administered as an initial 600 mg dose two 300 mg injections followed by 300 mg every two weeks via subcutaneous injection. The study uses a parallel design with participants randomly assigned in a 11 ratio to one of the two treatment groups. During the study, participants will be monitored for responses using measures such as the Eczema Area and Severity Index EASI at multiple time points up to week 52. The primary outcome is the proportion of patients achieving at least a 75% improvement in EASI score at week 16. Safety and treatment effects will be assessed through regular visits and evaluations over the course of the trial.
CONDITIONS
Brief Title
A Phase III Study of GS101 Injection to Dupixent®
Research Team
S
Sinian Li, Master
T
Tao Sun, Master
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here